EYPT Q4 2021 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+61.9% YoY

Gross Profit

$9M73.7% margin

Operating Income

-$18M-156.4% margin

Net Income

-$19M-168.3% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+27.4%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$263M

Total Liabilities

$79M

Stockholders' Equity

$184M

Cash & Equivalents

$179M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$7M	+61.9%
Gross Profit	$9M	$5M	+82.2%
Operating Income	-$18M	-$13M	-41.7%
Net Income	-$19M	-$15M	-25.6%

Revenue Segments

Product

$11M50%

Y U T I Q Product

$6M26%

D E X Y C U Product

$5M24%